Abacavir = ABC oral
Oral abacavir guidance for HIV treatment in combination with other antiretrovirals, including weight-based fixed-dose combination dosing.
View guide pageDrug Information
This section now covers all 162 oral-drug entries, all 71 injectable-drug entries, all 6 infusion-fluid entries, all 20 vaccine and antiserum entries, all 31 external-use and antiseptic entries, and all 14 potentially dangerous, obsolete, or ineffective entries from the source guideline. Each page keeps the original subheading structure and excludes the Storage and Remarks sections.
Browse 304 published medicine guides or search by drug name or alias.
Category
162
Oral drugs
Category
71
Injectable drugs
Category
6
Infusion fluids
Category
20
Vaccines and antisera
Category
31
External use and antiseptics
Category
14
Obsolete and dangerous
Oral abacavir guidance for HIV treatment in combination with other antiretrovirals, including weight-based fixed-dose combination dosing.
View guide pageAcetaminophen guidance for mild pain and fever with age-based dosing and overdose precautions.
View guide pageAspirin guidance for limited pain and fever use in older patients and for prevention of severe pre-eclampsia, with major bleeding precautions.
View guide pageOral aciclovir guidance for herpes and zoster, including treatment, prophylaxis, and route-specific dosing.
View guide pageAlbendazole dosing guidance for common helminth infections, including ascariasis, trichuriasis, strongyloidiasis, and trichinellosis.
View guide pageAntacid guidance for gastritis and peptic-ulcer-associated stomach pain, including dose timing and key interaction precautions.
View guide pageAmitriptyline guidance for neuropathic pain and major depression, including staged dose escalation and close-monitoring precautions.
View guide pageAmlodipine guidance for hypertension, including standard adult dosing, lower starting doses for higher-risk patients, and interaction precautions.
View guide pageAmoxicillin guidance for common bacterial infections, with usual and high-dose regimens, duration guidance, and penicillin precautions.
View guide pageCo-amoxiclav guidance for selected bacterial infections, with ratio-specific strengths, indication-specific dosing, and major hepatic and allergy precautions.
View guide pageCo-artemether guidance for uncomplicated malaria and completion treatment after severe malaria, with weight-based 3-day dosing.
View guide pageArtesunate/amodiaquine guidance for uncomplicated malaria and completion treatment after severe malaria, with once-daily dosing for 3 days.
View guide pageVitamin C guidance for treatment and prevention of scurvy, with age-based dosing and dose-related precaution notes.
View guide pageReference entry directing readers to the acetylsalicylic acid and ASA oral guidance.
View guide pageAtazanavir guidance for HIV treatment in combination therapy, including age and weight dosing and major interaction precautions.
View guide pageAzithromycin guidance for selected bacterial and chlamydial infections, with indication-based dosing and QT-related safety precautions.
View guide pageBeclometasone metered dose inhaler guidance for long-term chronic asthma treatment, including severity-based dosing and inhaler technique.
View guide pageBudesonide/formoterol metered dose inhaler guidance for long-term chronic asthma treatment, including moderate and severe persistent asthma dosing.
View guide pageIpratropium bromide metered dose inhaler guidance for severe asthma attack in combination with salbutamol.
View guide pageIpratropium bromide nebuliser solution guidance for severe asthma attack in combination with salbutamol.
View guide pageSalmeterol metered dose inhaler guidance for long-term treatment of moderate and severe persistent asthma with inhaled corticosteroid therapy.
View guide pageBiperiden guidance for extrapyramidal reactions caused by antipsychotics, including daily limits, elderly precautions, and anticholinergic risks.
View guide pageBisacodyl guidance for opioid-related constipation prevention and short-term constipation treatment, with bowel-response monitoring precautions.
View guide pageBisoprolol guidance for hypertension, angina, and stable heart failure, including gradual titration and abrupt-stop warning.
View guide pageReference entry directing readers to the hyoscine butylbromide oral guidance.
View guide pageCabergoline guidance for inhibition or suppression of lactation after fetal or neonatal loss, with postpartum safety restrictions.
View guide pageFolinic acid guidance for preventing pyrimethamine-related hematologic toxicity during toxoplasmosis and isosporiasis care.
View guide pageCarbamazepine guidance for epilepsy, neuropathic pain, and bipolar recurrence prevention, with gradual titration and close monitoring.
View guide pageCefalexin guidance for common staphylococcal and streptococcal skin infections, including neonatal and pediatric dosing.
View guide pageCefixime guidance for typhoid fever, selected urinary infections, gonorrhea, and second-line shigellosis treatment.
View guide pageActivated charcoal guidance for selected poisonings, including early dosing and repeated-dose follow-up when needed.
View guide pageChloroquine guidance for chloroquine-sensitive non-falciparum malaria, with base-dose clarification and cardiac precaution notes.
View guide pageChlorpromazine guidance for acute and chronic psychosis when other antipsychotics fail or are not tolerated, with close safety monitoring.
View guide pageEffervescent cimetidine guidance for prophylaxis of acid pulmonary aspiration syndrome in anesthesia settings.
View guide pageCiprofloxacin guidance for selected bacterial infections including shigellosis, pyelonephritis, plague, and anthrax, with tendon and QT precautions.
View guide pageClarithromycin guidance for Helicobacter pylori eradication in combination therapy, with renal and QT precautions.
View guide pageClindamycin guidance for severe staphylococcal and streptococcal infections, anthrax, and oral completion therapy after parenteral treatment.
View guide pageCloxacillin guidance for impetigo, with adolescent and adult dosing plus penicillin allergy precautions.
View guide pageReference entry directing readers to the amoxicillin and clavulanic acid oral guidance.
View guide pageReference entry directing readers to the artemether and lumefantrine oral guidance.
View guide pageCodeine guidance for short-term moderate pain treatment, with dependence and respiratory depression precautions.
View guide pageVitamin D3 guidance for prevention and treatment of vitamin D deficiency, with neonatal, child, adult, and pregnancy dosing.
View guide pageCo-trimoxazole guidance for toxoplasmosis, pneumocystosis, isosporiasis, brucellosis, and prophylaxis, with sulfonamide safety cautions.
View guide pageDapsone guidance for pneumocystosis and toxoplasmosis prophylaxis, pneumocystosis treatment, and leprosy combination therapy.
View guide pageDarunavir guidance for HIV treatment with ritonavir boosting, including separate schedules for protease-inhibitor-naive and experienced patients.
View guide pageDesogestrel guidance for progestogen-only oral contraception, including missed-pill instructions and postpartum timing.
View guide pageDexamethasone guidance for severe allergic and inflammatory reactions, with dose ranges based on severity and short-course taper cautions.
View guide pageDiazepam guidance for short-term severe anxiety, insomnia, and agitation, with dependence and sedation precautions.
View guide pageDiethylcarbamazine guidance for lymphatic filariasis, with staged dose escalation and severe co-infection precautions.
View guide pageDigoxin guidance for supraventricular arrhythmias and heart failure, with narrow therapeutic window precautions.
View guide pageDihydroartemisinin and piperaquine guidance for uncomplicated malaria and post-parenteral completion therapy, with weight-based 3-day dosing.
View guide pageDolutegravir guidance for HIV treatment across infant, child, adolescent, and adult weights, with interaction-based dose adjustments.
View guide pageDoxycycline guidance for a broad range of bacterial and parasitic infections, including plague, rickettsioses, syphilis, and leptospirosis.
View guide pageEfavirenz guidance for HIV treatment in combination therapy, including weight-based pediatric dosing and neuropsychiatric precautions.
View guide pageEnalapril guidance for hypertension and heart failure, with renal monitoring and hyperkalaemia precautions.
View guide pageVitamin D2 guidance for prevention and treatment of vitamin D deficiency using the same doses as colecalciferol.
View guide pageErythromycin guidance for selected bacterial infections including pertussis, pneumonia, diphtheria, and chlamydial infections.
View guide pageEthambutol guidance for tuberculosis combination therapy, with optic neuritis monitoring precautions.
View guide pageCombined oral contraceptive guidance for contraception and functional uterine bleeding, with missed-pill and thromboembolic risk precautions.
View guide pageFerrous salts guidance for prevention of iron deficiency and treatment of iron-deficiency anemia across neonatal, child, and adult ages.
View guide pageFixed-dose iron and folic acid combination guidance mainly for prevention of deficiency during pregnancy.
View guide pageFluconazole guidance for candidiasis, cryptococcal meningitis, and secondary prophylaxis, with renal, hepatic, and QT precautions.
View guide pageFlucytosine guidance for induction-phase cryptococcal meningitis in combination therapy, with blood count and renal monitoring needs.
View guide pageFluoxetine guidance for major depression, generalized anxiety, and severe post-traumatic stress disorder, with gradual withdrawal advice.
View guide pageFolic acid guidance for folate-deficient megaloblastic anemia, with key exclusions for antifolate-related anemia.
View guide pageFosfomycin guidance for uncomplicated cystitis and asymptomatic bacteriuria in pregnancy, using single-dose therapy.
View guide pageFurosemide guidance for edema associated with renal, hepatic, or congestive heart failure, with potassium and dehydration precautions.
View guide pageGlibenclamide guidance for second-line type 2 diabetes treatment in patients under 60 years, with weekly titration and hypoglycemia precautions.
View guide pageGliclazide guidance for second-line type 2 diabetes treatment in patients over 60 years, with slower titration and hypoglycemia precautions.
View guide pageSublingual nitroglycerin guidance for short-term angina prophylaxis, acute angina treatment, and adjunctive therapy in acute heart failure.
View guide pageGriseofulvin guidance for dermatophyte infections of the scalp, skin, and folds, with long-course dosing and pregnancy contraindication.
View guide pageHaloperidol guidance for delirium, psychosis, mania, and severe agitation, with QT and extrapyramidal precautions.
View guide pageHydrochlorothiazide guidance for hypertension and edema, with electrolyte and pregnancy contraindications.
View guide pageHydroxyzine guidance for moderate anxiety and insomnia, with QT and anticholinergic precautions.
View guide pageHyoscine butylbromide guidance for gastrointestinal and genitourinary tract spasms, with anticholinergic safety limits.
View guide pageIbuprofen guidance for pain, fever, and rheumatic disease, with age-based dosing and NSAID safety precautions.
View guide pageIodized oil guidance for prevention and treatment of severe iodine deficiency with annual dosing by age group.
View guide pageIsoniazid guidance for tuberculosis and latent tuberculosis protocols, with pyridoxine support and hepatotoxicity precautions.
View guide pageIsosorbide dinitrate guidance for angina prophylaxis, chronic heart failure, and acute angina rescue, with nitrate safety precautions.
View guide pageItraconazole guidance for histoplasmosis, penicilliosis, prophylaxis, and scalp dermatophytosis, with interaction and heart failure precautions.
View guide pageIvermectin guidance for onchocerciasis and scabies, with special caution in regions where loiasis is endemic.
View guide pageLabetalol guidance for hypertension in pregnancy, with beta-blocker precautions and neonatal monitoring advice.
View guide pageLactulose guidance for prevention of constipation in patients taking opioid analgesics, with stool-response monitoring.
View guide pageLamivudine guidance for HIV treatment with weight-based tablet and oral-solution dosing across infants, children, and adults.
View guide pageLevetiracetam guidance for generalized tonic-clonic, focal, and absence seizures, with gradual titration and behavioral monitoring.
View guide pageLevodopa and carbidopa guidance for Parkinson's disease and non-antipsychotic extrapyramidal disorders, with gradual titration and psychiatric precautions.
View guide pageLevonorgestrel progestogen-only pill guidance for oral contraception, with strict timing and missed-pill rules.
View guide pageEmergency levonorgestrel guidance for unprotected intercourse, including extended-window use and enzyme-inducer dose adjustment.
View guide pageLoperamide guidance for persistent diarrhea in adults with HIV, always alongside rehydration.
View guide pageLopinavir and ritonavir guidance for HIV treatment with age- and weight-based dosing, plus rifampicin and QT interaction precautions.
View guide pageLoratadine guidance for minor allergic reactions, with reduced-dose use in severe renal or hepatic impairment.
View guide pageMebendazole guidance for common helminth infections and trichinellosis, with age cutoffs and pregnancy caution.
View guide pageOral medroxyprogesterone guidance for abnormal uterine bleeding, distinct from the injectable contraceptive form.
View guide pageMetformin guidance as first-line treatment of type 2 diabetes, with stepwise titration and renal-function precautions.
View guide pageMethyldopa guidance for hypertension in pregnancy, with gradual titration and hepatic monitoring precautions.
View guide pageMetoclopramide guidance for symptomatic nausea and vomiting in adults, with strict duration and neurological safety limits.
View guide pageMetronidazole guidance for protozoal and anaerobic infections, with indication-specific schedules and alcohol precautions.
View guide pageMiconazole oral gel guidance for mild oropharyngeal candidiasis, with swallowing safety precautions in young children.
View guide pageMifepristone guidance for termination of intra-uterine pregnancy up to 22 weeks when combined with misoprostol.
View guide pageMisoprostol guidance for incomplete abortion, termination of pregnancy, induction of labour, postpartum hemorrhage, and cervical dilation.
View guide pageImmediate-release oral morphine guidance for severe pain, with scheduled dosing, rescue doses, and conversion toward sustained-release morphine.
View guide pageSustained-release oral morphine guidance for severe persistent pain, especially cancer pain, including rescue-dose logic.
View guide pageGeneral multivitamin supplementation guidance with limited indications and no role in true vitamin-deficiency treatment.
View guide pageNevirapine guidance for prevention of mother-to-child HIV transmission in neonates, with age-based dosing and severe rash/hepatotoxicity precautions.
View guide pageNiclosamide guidance for taeniasis including beef, pork, dwarf, and fish tapeworm infections.
View guide pageNicotinamide guidance for pellagra treatment with repeated daily dosing until full clinical recovery.
View guide pageImmediate-release nifedipine guidance for threatened premature labour, with short-course dosing and cardiovascular precautions.
View guide pageNitrofurantoin guidance for uncomplicated cystitis when other antibiotics cannot be used, with renal and G6PD precautions.
View guide pageReference entry directing readers to the glyceryl trinitrate oral guidance.
View guide pageNystatin oral suspension guidance for mild oropharyngeal candidiasis, with between-meal use and local administration advice.
View guide pageOlanzapine guidance for psychosis and acute manic episode when other antipsychotics are not tolerated or have failed.
View guide pageOmeprazole guidance for gastro-oesophageal reflux and adult gastric or duodenal ulcers, with age-weight dosing and interaction precautions.
View guide pageORS guidance for preventing and treating dehydration from acute diarrhoea and cholera using WHO treatment plans A, B, and C.
View guide pageParacetamol guidance for mild pain and fever with age-based dosing and overdose precautions.
View guide pageParoxetine guidance for major depression, generalised anxiety, and severe post-traumatic stress disorder, with tapering and interaction precautions.
View guide pagePhenobarbital guidance for tonic-clonic and focal epilepsy, with gradual titration and close safety monitoring.
View guide pagePhenoxymethylpenicillin guidance for streptococcal pharyngitis, scarlet fever, and diphtheria completion therapy.
View guide pagePhenytoin guidance for tonic-clonic and focal epilepsy, with careful titration because of nonlinear kinetics and toxicity risk.
View guide pageImmediate-release potassium chloride guidance for moderate hypokalaemia when a rapid oral effect is required.
View guide pageSustained-release potassium chloride guidance for diuretic-induced hypokalaemia during longer-term replacement.
View guide pagePraziquantel guidance for schistosomiasis, taeniasis, and several fluke infections, with organism-specific dosing.
View guide pagePrednisolone and prednisone guidance for allergic and inflammatory conditions, with tapering advice for longer courses.
View guide pagePromethazine guidance for short-term insomnia and for agitation with haloperidol in psychosis, with strong sedation precautions.
View guide pagePyrazinamide guidance for tuberculosis in combination therapy, with renal adjustment and hepatotoxicity precautions.
View guide pagePyridoxine guidance for prevention and treatment of isoniazid-induced peripheral neuropathy.
View guide pagePyrimethamine guidance for toxoplasmosis and isosporiasis in immunodeficient patients, with folate-deficiency precautions.
View guide pageQuinine guidance for uncomplicated falciparum malaria and completion treatment after severe malaria when artemisinin combinations cannot be used.
View guide pageReSoMal guidance for prevention and treatment of dehydration in children with complicated acute malnutrition only.
View guide pageRetinol guidance for prevention and treatment of vitamin A deficiency, including xerophthalmia and measles supplementation.
View guide pageRifampicin guidance for tuberculosis, latent tuberculosis, leprosy, and brucellosis, with major interaction precautions.
View guide pageRifapentine guidance for latent tuberculosis in combination with isoniazid, with weekly and daily regimens.
View guide pageRisperidone guidance for psychosis and acute manic episode when other antipsychotics are not tolerated or have failed.
View guide pageRitonavir booster guidance for protease inhibitors in HIV infection, with hepatic and interaction precautions.
View guide pageSertraline guidance for major depression and severe post-traumatic stress disorder, with tapering and interaction precautions.
View guide pageReference entry directing readers to the valproic acid oral guidance.
View guide pageSofosbuvir and daclatasvir guidance for chronic hepatitis C across several genotypes and cirrhosis states.
View guide pageSofosbuvir and velpatasvir guidance for chronic hepatitis C across genotypes with or without cirrhosis.
View guide pageSpironolactone guidance for oedema associated with heart failure, hepatic cirrhosis, and nephrotic syndrome.
View guide pageSulfadiazine guidance for treatment and secondary prophylaxis of toxoplasmosis in immunodeficient patients.
View guide pageSulfadoxine-pyrimethamine guidance for intermittent preventive treatment of malaria in pregnancy in Africa.
View guide pageReference entry directing readers to the co-trimoxazole oral guidance.
View guide pageTenofovir guidance for HIV infection and chronic hepatitis B, with renal and bone precautions.
View guide pageThiamine guidance for vitamin B1 deficiencies including beriberi and alcoholic neuritis.
View guide pageTinidazole guidance for amoebiasis, giardiasis, trichomoniasis, bacterial vaginitis, and anaerobic infections.
View guide pageTramadol guidance for short-term moderate pain treatment, with dependence and seizure precautions.
View guide pageTranexamic acid guidance for abnormal uterine bleeding unrelated to pregnancy, with thromboembolic precautions.
View guide pageTriclabendazole guidance for fascioliasis and paragonimiasis, with benzimidazole-allergy precautions.
View guide pageTrihexyphenidyl guidance for second-line treatment of antipsychotic-induced extrapyramidal reactions, with anticholinergic precautions.
View guide pageReference entry directing readers to the glyceryl trinitrate oral guidance.
View guide pageUlipristal guidance for emergency contraception up to 120 hours after unprotected intercourse.
View guide pageValproic acid guidance for epilepsy and prevention of recurrence of bipolar disorder, with major pregnancy and safety warnings.
View guide pageReference entry directing readers to the retinol oral guidance.
View guide pageReference entry directing readers to the thiamine oral guidance.
View guide pageReference entry directing readers to the nicotinamide oral guidance.
View guide pageReference entry directing readers to the pyridoxine oral guidance.
View guide pageReference entry directing readers to the folic acid oral guidance.
View guide pageReference entry directing readers to the ascorbic acid oral guidance.
View guide pageReference entry directing readers to the ergocalciferol oral guidance.
View guide pageReference entry directing readers to the colecalciferol oral guidance.
View guide pageReference entry directing readers to the nicotinamide oral guidance.
View guide pageZidovudine guidance for HIV treatment and prevention of mother-to-child transmission, with haematologic precautions.
View guide pageZinc sulfate guidance as an adjunct to oral rehydration therapy for acute or persistent diarrhoea in children under 5 years.
View guide pageSalbutamol injectable guidance for threatened premature labour, with infusion titration and high-risk maternal monitoring precautions.
View guide pageInjectable co-amoxiclav guidance for cellulitis, necrotizing infections, and severe postpartum upper genital tract infection.
View guide pageConventional amphotericin B guidance for cryptococcal meningitis induction and severe systemic fungal infections, with major renal-toxicity precautions.
View guide pageLiposomal amphotericin B guidance for selected severe fungal disease and leishmaniasis, with reduced nephrotoxicity compared with conventional amphotericin.
View guide pageInjectable ampicillin guidance for severe bacterial infections and severe cutaneous anthrax, with neonatal IV use instructions.
View guide pageTwo-step injectable artesunate guidance for severe malaria and initial treatment when oral therapy is not possible.
View guide pageOne-step artesunate injectable guidance for severe malaria, using the arginine and sodium bicarbonate solvent formulation.
View guide pageAtropine injectable guidance for anaesthesia premedication, gastrointestinal spasms, and organophosphorus pesticide poisoning.
View guide pageAzithromycin injectable guidance for severe macrolide-sensitive infections when oral treatment is not possible.
View guide pageLong-acting benzathine benzylpenicillin guidance for syphilis, endemic treponematoses, tonsillitis, and rheumatic-fever prophylaxis.
View guide pageShort-acting benzylpenicillin guidance for diphtheria, severe leptospirosis, neurosyphilis, and congenital syphilis.
View guide pageLong-acting procaine benzylpenicillin guidance for diphtheria and congenital syphilis when oral treatment is not possible.
View guide pageCalcium gluconate guidance for severe hypocalcaemia and magnesium sulfate intoxication, with IV-only use and hypercalcaemia precautions.
View guide pageCefotaxime guidance for meningitis, urinary infection, pneumonia, and gonococcal conjunctivitis, with neonatal dosing included.
View guide pageCeftriaxone guidance for severe bacterial infections and gonococcal disease, with IM and IV administration rules.
View guide pageChloramphenicol guidance for plague meningitis, with age restriction and haematologic-toxicity precautions.
View guide pageInjectable clindamycin guidance for severe anaerobic, streptococcal, and staphylococcal infections, plus necrotizing infections and anthrax.
View guide pageInjectable cloxacillin guidance for severe streptococcal and staphylococcal infections and for erysipelas or cellulitis.
View guide pageInjectable dexamethasone guidance for severe allergic or inflammatory reactions and for foetal lung maturation before 34 weeks.
View guide pageInjectable diazepam guidance for convulsive status epilepticus, tetanus-related muscle spasms, and severe adult agitation.
View guide pageInjectable diclofenac guidance for short-term moderate inflammatory pain, with strict duration and pregnancy restrictions.
View guide pageInjectable digoxin guidance for supraventricular arrhythmias and heart failure, with a narrow therapeutic range.
View guide pageInjectable eflornithine guidance for meningoencephalitic African trypanosomiasis due to T.b. gambiense.
View guide pageEpinephrine injectable guidance for severe anaphylaxis and shock-related hypotension, with IM first-line and IV use only in equipped hospitals.
View guide pageEtonogestrel implant guidance for long-acting contraception, with insertion timing and enzyme-inducer precautions.
View guide pageInjectable fluconazole guidance for severe fungal infections when oral treatment is not possible.
View guide pageInjectable furosemide guidance for emergency oedema management, hypertensive crisis, and pulmonary oedema.
View guide pageInjectable gentamicin guidance for severe bacterial infections, with renal and auditory toxicity precautions.
View guide pageHypertonic glucose guidance for severe hypoglycaemia in adults, with warnings about extravasation and pediatric dilution.
View guide pageInjectable haloperidol guidance for delirium, acute alcohol intoxication, and agitation in psychosis, with strong safety monitoring.
View guide pageLong-acting haloperidol decanoate guidance for maintenance treatment of chronic psychosis after stabilization with oral haloperidol.
View guide pageHeparin sodium guidance for curative and preventive anticoagulation, requiring coagulation monitoring and careful administration.
View guide pageInjectable hydralazine guidance for severe hypertension in pregnancy when oral treatment is not possible.
View guide pageInjectable hydrocortisone guidance for severe allergic or inflammatory reactions when oral treatment is not possible.
View guide pageInjectable hyoscine butylbromide guidance for gastrointestinal and genitourinary spasms, with anticholinergic precautions.
View guide pageGeneral insulin guidance covering SC use principles, indications, dose individualization, and major safety precautions.
View guide pageShort-acting insulin guidance for diabetes and emergency treatment of severe hyperglycaemia.
View guide pageBiphasic insulin guidance for diabetes, combining short-acting and intermediate-acting insulin for SC use only.
View guide pageIsosorbide dinitrate injectable guidance for adjunctive treatment of acute heart failure with pulmonary oedema.
View guide pageKetamine injectable guidance for induction and maintenance of general anaesthesia.
View guide pageLabetalol injectable guidance for severe hypertension in pregnancy when oral treatment is not possible.
View guide pageLevetiracetam injectable guidance for second-line treatment of convulsive status epilepticus.
View guide pageLevonorgestrel implant guidance for long-acting contraception with duration and insertion precautions.
View guide pageLidocaine injectable guidance for local anaesthesia in minor operations and dental surgery.
View guide pageMagnesium sulfate injectable guidance for severe pre-eclampsia and eclampsia with close monitoring requirements.
View guide pageMedroxyprogesterone acetate injectable guidance for long-acting contraception and functional uterine bleeding.
View guide pageMelarsoprol injectable guidance for meningoencephalitic African trypanosomiasis with high-toxicity precautions.
View guide pageMethylergometrine injectable guidance for postpartum haemorrhage due to uterine atony.
View guide pageMetoclopramide injectable guidance for prevention or symptomatic treatment of nausea and vomiting in adults.
View guide pageMetronidazole injectable guidance for severe anaerobic bacterial infections.
View guide pageMidazolam guidance for first-line treatment of convulsive status epilepticus by buccal, intranasal, or IM routes.
View guide pageMorphine injectable guidance for severe pain in surgery, trauma, and neoplastic disease.
View guide pageNaloxone injectable guidance for opioid-induced respiratory depression with IV, IM, and infusion use.
View guide pageNorepinephrine injectable guidance for acute hypotension despite fluid therapy in shock.
View guide pageOmeprazole injectable guidance for peptic ulcer perforation when IV proton pump inhibition is needed.
View guide pageOndansetron injectable guidance for postoperative nausea and vomiting in children and adults.
View guide pageOxytocin guidance for labour induction and prevention or treatment of postpartum haemorrhage.
View guide pageIV paracetamol guidance for very high fever and mild pain only when oral administration is not possible.
View guide pagePentamidine guidance for second-line treatment of pneumocystosis when co-trimoxazole cannot be used.
View guide pagePhenobarbital guidance for second-line treatment of convulsive status epilepticus.
View guide pagePhenytoin guidance for second-line treatment of convulsive status epilepticus with strict infusion requirements.
View guide pageVitamin K1 guidance for prophylaxis and treatment of haemorrhagic disease of the newborn.
View guide pagePotassium chloride 15% injectable guidance for severe hypokalaemia, with dilution-only IV infusion dosing and monitoring precautions.
View guide pagePromethazine guidance for agitation or aggressive behaviour in acute or chronic psychosis with haloperidol.
View guide pageProtamine guidance for neutralising the anticoagulant effects of heparin and enoxaparin.
View guide pageHypertonic sodium bicarbonate guidance for severe metabolic acidosis under close supervision.
View guide pageStreptomycin guidance as an alternative in plague and for brucellosis with doxycycline.
View guide pageSuramin guidance for haemolymphatic African trypanosomiasis due to T. b. rhodesiense.
View guide pageInjectable thiamine guidance for severe vitamin B1 deficiency, acute beriberi, and neurological complications of alcoholism.
View guide pageTramadol guidance for moderate pain with oral step-down as soon as possible.
View guide pageTranexamic acid guidance for postpartum haemorrhage, abnormal uterine bleeding, and trauma-associated haemorrhage.
View guide pageValproic acid guidance for second-line treatment of convulsive status epilepticus with strict pregnancy restrictions.
View guide pageGeneral infusion-fluid safety checks covering labelling, compatibility, contamination, and visual inspection before use.
View guide pageGlucose 5% guidance as an IV infusion vehicle, with compatibility limits and low nutritional value.
View guide pageGlucose 10% guidance for treatment of hypoglycaemia, including IV dosing and preparation if a ready-made solution is unavailable.
View guide pageRinger lactate guidance for severe dehydration and fluid replacement, with key composition and caution notes.
View guide page0.9% sodium chloride guidance for IV drug delivery and fluid replacement, including sodium-retention precautions.
View guide page3% sodium chloride guidance for severe symptomatic hyponatraemia, traumatic brain injury, and cerebral oedema under close supervision.
View guide pageOral cholera vaccine guidance for prevention in epidemic, endemic, and humanitarian emergency contexts.
View guide pagePentavalent vaccine guidance for prevention of diphtheria, tetanus, pertussis, hepatitis B, and severe Hib infections in children.
View guide pageHepatitis B vaccine guidance covering birth dose, standard schedules, and accelerated schedules when rapid protection is needed.
View guide pageJapanese encephalitis vaccine guidance for people in endemic areas and higher-risk travellers.
View guide pageMeasles vaccine guidance for routine and catch-up vaccination, including earlier dosing in higher-risk settings.
View guide pageMeningococcal A conjugate vaccine guidance for prevention of meningitis due to meningococcus A in the African meningitis belt.
View guide pageMeningococcal A+C vaccine guidance for outbreaks and higher-risk travel in hyperendemic areas.
View guide pageMeningococcal A+C+W135 vaccine guidance for outbreak control and high-risk travel in hyperendemic areas.
View guide pageHPV vaccine guidance for prevention of premalignant anogenital lesions, cervical cancer, and certain anogenital warts.
View guide pagePCV guidance for prevention of invasive pneumococcal infection, pneumonia, and acute otitis media in children from 6 weeks of age.
View guide pageIPV guidance for prevention of poliomyelitis, alone or alongside oral poliomyelitis vaccine schedules.
View guide pageOral poliomyelitis vaccine guidance for prevention of poliomyelitis in combination with IPV.
View guide pageHRIG guidance for category III rabies exposure and immunocompromised category II or III exposure, alongside rabies vaccine.
View guide pageRabies vaccine guidance for post-exposure prevention, with IM and intradermal schedules based on vaccination status.
View guide pageOral rotavirus vaccine guidance for prevention of rotavirus gastroenteritis in children up to 24 months of age.
View guide pageHTIG guidance for wound-related tetanus prevention and for treatment of clinical tetanus.
View guide pageTd vaccine guidance for wound management, pregnancy, childbearing age, and booster protection after primary vaccination.
View guide pageBCG vaccine guidance for tuberculosis prevention, including intradermal technique and local-reaction expectations.
View guide pageTCV guidance for prevention of typhoid fever in endemic areas and outbreak or emergency campaigns.
View guide pageYellow fever vaccine guidance for people in endemic areas, travellers, and outbreak campaigns.
View guide pagePovidone iodine aqueous solution guidance for intact or broken skin and mucous-membrane antisepsis.
View guide pageAciclovir eye ointment guidance for herpes keratitis and neonatal prevention when maternal genital herpes is present at childbirth.
View guide pageABHR guidance for antiseptic handrubbing before and after procedures when hands are not visibly soiled.
View guide pageRectal artesunate guidance for pre-referral treatment of suspected or confirmed severe malaria in young children.
View guide pageWhitfield's ointment guidance for localized dermatophyte infections and as adjunctive care for more extensive lesions.
View guide pageBenzyl benzoate lotion guidance for scabies, with age-based dilution and contact-time instructions.
View guide pageCalamine lotion guidance for symptomatic treatment of pruritus.
View guide pageAlcohol-based chlorhexidine guidance for intact-skin antisepsis before punctures and surgery.
View guide pageConcentrated chlorhexidine guidance for diluted use on small or superficial wounds and burns.
View guide pageChlorhexidine dermal gel guidance for umbilical-cord antisepsis and adjunctive treatment of omphalitis.
View guide pageChlorhexidine mouthwash guidance for antisepsis of noma mouth ulcers, with local-application instructions and key precautions.
View guide pageChlorhexidine soap guidance for surgical hand scrubbing, preoperative cleansing, and wound cleansing.
View guide pageCiprofloxacin ear-drop guidance for acute otitis externa and chronic suppurative otitis media, with age-based dosing.
View guide pageClotrimazole vaginal-tablet guidance for vaginal candidiasis, including single-dose administration and pregnancy precautions.
View guide pageDimeticone lotion guidance for head lice, with contact-time instructions and repeat treatment after 7 days.
View guide pageFluorescein eye-drop guidance for detecting corneal or conjunctival epithelial damage during examination.
View guide pageTopical hydrocortisone guidance for selected eczematous and bite reactions, with strict short-course precautions.
View guide pageLevonorgestrel IUD guidance for long-acting contraception and functional uterine bleeding, including insertion timing and major precautions.
View guide pageMiconazole cream guidance for cutaneous candidiasis, candidal balanitis, and mild dermatophyte infections.
View guide pageMupirocin ointment guidance for localized non-bullous impetigo, including reassessment and escalation criteria.
View guide pageNystatin vaginal-tablet guidance for vaginal candidiasis, with bedtime administration and 14-day treatment duration.
View guide pageOxybuprocaine eye-drop guidance for short-term anaesthesia of the conjunctiva and cornea during brief procedures.
View guide pagePermethrin 1% lotion guidance for head lice, with 10-minute contact time and repeat treatment after 7 days.
View guide pagePermethrin 5% cream guidance for scabies, including whole-body application and repeat treatment after 7 days.
View guide pagePilocarpine eye-drop guidance for chronic open-angle glaucoma, with long-term dosing and retinal precautions.
View guide pagePodophyllotoxin guidance for selected genital and perianal warts, with short treatment cycles and strict safety limits.
View guide pagePodophyllum resin guidance for selected genital and perianal warts, with protective application and toxicity precautions.
View guide pagePovidone iodine scrub-solution guidance for surgical hand scrubbing, preoperative cleansing, and wound cleansing.
View guide pageSilver sulfadiazine cream guidance for severe-burn infections and infected leg ulcers, with sterile application and sulfonamide precautions.
View guide pageTetracycline eye-ointment guidance for conjunctivitis, trachoma, and neonatal conjunctivitis prevention.
View guide pageZinc oxide ointment guidance for skin protection in eczema, nappy rash, minor burns, and other irritant conditions.
View guide pageAmodiaquine guidance for malaria treatment when used with artesunate, with key interaction and prior-toxicity precautions.
View guide pageArtemether injectable guidance for severe malaria when artesunate is unavailable, with oily IM dosing and weight-band examples.
View guide pageOral artesunate guidance for malaria treatment only when used in co-formulated combinations with another antimalarial.
View guide pageArtesunate plus sulfadoxine-pyrimethamine guidance for falciparum malaria, with blister-pack dosing by weight.
View guide pageLong-acting oily chloramphenicol guidance for meningococcal meningitis during epidemics, with single-dose IM use and haematologic precautions.
View guide pageMefloquine guidance for malaria treatment with artesunate, with neuropsychiatric and cardiac precautions.
View guide pageGentian violet guidance for limited candidiasis and wet skin lesions, with preparation steps and strong safety cautions.
View guide pageMetamizole oral guidance for pain and fever, with warnings about agranulocytosis and severe allergy.
View guide pageMetamizole injectable guidance for pain and fever, with serious agranulocytosis and anaphylaxis warnings.
View guide pagePotassium chloride 10% injectable guidance for severe hypokalaemia, with dilution-only use and infusion monitoring.
View guide pageQuinine injectable guidance for severe malaria when artesunate is unavailable, with loading-dose and maintenance infusion dosing.
View guide pageEquine tetanus antitoxin guidance retained as an obsolete reference, with dosing for wound prophylaxis and clinical tetanus plus hypersensitivity precautions.
View guide pageDTP vaccine guidance retained as a replaced reference, with primary and booster schedules and standard precautions.
View guide page